Further 'Slight Modifications' To Advisory Panel Process Likely
This article was originally published in The Gray Sheet
Executive Summary
FDA's device center said it will continue to assess its advisory panel process, a week after the first two meetings were held without the traditional up-or-down vote on device approvability
You may also be interested in...
Device Panel Reforms: FDA Puts An End To Approvability Votes
FDA advisory panel members will no longer take an up or down vote on the approvability of medical devices, or on recommended conditions of approval, CDRH announced April 26
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.